Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 1Osteoporosis, Postmenopausal 1Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × LY 353381 × Clear all
NCT00005879 2017-05-30

LY353381 in Preventing Breast Cancer in Women With Hyperplasia

University of Kansas Medical Center

Phase 2 Completed
199 enrolled 16 charts
Breast

Breast Neoplasms

NCT00088010 2010-06-02

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

Eli Lilly and Company

Phase 3 Completed
9,369 enrolled

Osteoporosis, Postmenopausal

NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00034125 2006-07-19

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Eli Lilly and Company

Phase 3 Completed
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡